Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...

By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a gene-editing biotechnology based on clustered regularly interspaced short ...

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...

SkyQuest Technology Consulting published a report, titled, Cell Therapy Market - Global Opportunity Analysis and Industry ...

The US biopharma has planted roots in the UK’s biotech cluster as it bets on synthetic rescue to unlock new treatments for rare diseases.